Exact Mass: 321.96787340000003
Exact Mass Matches: 321.96787340000003
Found 79 metabolites which its exact mass value is equals to given mass value 321.96787340000003,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Chloramphenicol
An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) G - Genito urinary system and sex hormones > G01 - Gynecological antiinfectives and antiseptics > G01A - Antiinfectives and antiseptics, excl. combinations with corticosteroids > G01AA - Antibiotics D - Dermatologicals > D10 - Anti-acne preparations > D10A - Anti-acne preparations for topical use > D10AF - Antiinfectives for treatment of acne D - Dermatologicals > D06 - Antibiotics and chemotherapeutics for dermatological use > D06A - Antibiotics for topical use S - Sensory organs > S03 - Ophthalmological and otological preparations > S03A - Antiinfectives > S03AA - Antiinfectives J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01B - Amphenicols > J01BA - Amphenicols S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AA - Antibiotics S - Sensory organs > S02 - Otologicals > S02A - Antiinfectives > S02AA - Antiinfectives D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3070 C254 - Anti-Infective Agent > C258 - Antibiotic C784 - Protein Synthesis Inhibitor KEIO_ID C057; [MS3] KO008919 KEIO_ID C057; [MS2] KO008918 KEIO_ID C057
Minodronic acid
C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain[1][2].
Minodronic acid
C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain[1][2].
Trofosfamide
C9H18Cl3N2O2P (322.01714280000004)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01A - Alkylating agents > L01AA - Nitrogen mustard analogues D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D010752 - Phosphoramide Mustards C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D009676 - Noxae > D000477 - Alkylating Agents D009676 - Noxae > D009153 - Mutagens
chloramphenicol
G - Genito urinary system and sex hormones > G01 - Gynecological antiinfectives and antiseptics > G01A - Antiinfectives and antiseptics, excl. combinations with corticosteroids > G01AA - Antibiotics D - Dermatologicals > D10 - Anti-acne preparations > D10A - Anti-acne preparations for topical use > D10AF - Antiinfectives for treatment of acne An organochlorine compound that is dichloro-substituted acetamide containing a nitrobenzene ring, an amide bond and two alcohol functions. D - Dermatologicals > D06 - Antibiotics and chemotherapeutics for dermatological use > D06A - Antibiotics for topical use S - Sensory organs > S03 - Ophthalmological and otological preparations > S03A - Antiinfectives > S03AA - Antiinfectives J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01B - Amphenicols > J01BA - Amphenicols S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AA - Antibiotics S - Sensory organs > S02 - Otologicals > S02A - Antiinfectives > S02AA - Antiinfectives D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic C784 - Protein Synthesis Inhibitor CONFIDENCE standard compound; INTERNAL_ID 662; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3461; ORIGINAL_PRECURSOR_SCAN_NO 3459 CONFIDENCE standard compound; INTERNAL_ID 662; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3476; ORIGINAL_PRECURSOR_SCAN_NO 3473 CONFIDENCE standard compound; INTERNAL_ID 662; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3449; ORIGINAL_PRECURSOR_SCAN_NO 3445 CONFIDENCE standard compound; INTERNAL_ID 662; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3469; ORIGINAL_PRECURSOR_SCAN_NO 3467 CONFIDENCE standard compound; INTERNAL_ID 662; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3457; ORIGINAL_PRECURSOR_SCAN_NO 3455 CONFIDENCE standard compound; INTERNAL_ID 662; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3458; ORIGINAL_PRECURSOR_SCAN_NO 3457 Origin: Microbe, Propylene glycols, Nitrobenzenes CONFIDENCE standard compound; INTERNAL_ID 2306 CONFIDENCE standard compound; INTERNAL_ID 8318 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.577 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.575 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.573 CONFIDENCE standard compound; INTERNAL_ID 4073
2-[(4-bromo-1,3-thiazol-2-yl)methyl]isoindole-1,3-dione
methyl 3-bromo-6-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
C10H6BrF3N2O2 (321.95647119999995)
Ethanone,1,1-(oxydi-4,1-phenylene)bis[2-chloro-
C16H12Cl2O3 (322.01634620000004)
Benzene,2,3-bis(bromomethyl)-1,4-dimethoxy-
C10H12Br2O2 (321.92039719999997)
3-(4-[(2,4-DICHLOROBENZYL)OXY]PHENYL)ACRYLIC ACID
C16H12Cl2O3 (322.01634620000004)
3-(4-((3,4-DICHLOROBENZYL)OXY)PHENYL)ACRYLIC ACID
C16H12Cl2O3 (322.01634620000004)
4-CHLORO-3-((3-CHLORO-5-(TRIFLUOROMETHYL)PYRIDIN-2-YL)OXY)ANILINE
4-bromo-2-(3-hydroxypropyl)-6-(trifluoromethyl)benzimidazole
2-Phospho-L-ascorbic acid trisodium salt
C6H6Na3O9P (321.9442556000001)
L-Ascorbic acid 2-phosphate trisodium (2-Phospho-L-ascorbic acid trisodium) is a long-acting vitamin C derivative that can stimulate collagen formation and expression[1]. L-Ascorbic acid 2-phosphate trisodium (2-Phospho-L-ascorbic acid trisodium) can be used as a culture medium supplement for the osteogenic differentiation of human adipose stem cells (hASCs). L-Ascorbic acid 2-phosphate trisodium (2-Phospho-L-ascorbic acid trisodium) increases alkaline phosphatase (ALP) activity and expression of runx2A in hASCs during the osteogenic differentiation[2][3].
Dichlorosulfophenyl-3-methylpyrazolone
C10H8Cl2N2O4S (321.95818280000003)
Nickel(2+) sulfamate hydrate (1:2:4)
H12N2NiO10S2 (321.92868419999996)
5-(BENZYLOXY)-4-BROMO-2-NITROANILINE
C13H11BrN2O3 (321.99529959999995)
4-iodo-1-[2-(oxan-2-yloxy)ethyl]pyrazole
C10H15IN2O2 (322.01782399999996)
1,2-bis(bromomethyl)-4,5-dimethoxybenzene
C10H12Br2O2 (321.92039719999997)
3-CHLORO-4-{[3-CHLORO-5-(TRIFLUOROMETHYL)-2-PYRIDINYL]OXY}ANILINE
3-(N-(4-CHLORO-3-METHYLISOXAZOL-5-YL)SULFAMOYL)THIOPHENE-2-CARBOXYLIC ACID
4,5-DICHLORO-2-(2,6-DICHLOROBENZYL)-2,3-DIHYDROPYRIDAZIN-3-ONE
C11H6Cl4N2O (321.92342260000004)
2-bromo-1-(4-chlorophenyl)-2-(4-methylphenyl)ethanone
Methyl 2-iodo-4,5-dimethoxybenzoate
C10H11IO4 (321.97020760000004)
Methyl 5-iodo-2,4-dimethoxybenzoate
C10H11IO4 (321.97020760000004)
ETHYL 3-[5-(CHLOROSULFONYL)-2-THIENYL]-1,2,4-OXADIAZOLE-5-CARBOXYLATE
nickel(ii) amidosulfate tetrahydrate
H12N2NiO10S2 (321.92868419999996)
5-Bromouridine
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D000970 - Antineoplastic Agents 5-Bromouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
N-(3,4-Dichlorophenyl)-P-methyl-N-(trifluoromethyl)phosphonamidic acid methyl ester
C9H10Cl2F3NO2P (321.97782860000007)
2-(2-iodo-4,5-dimethoxy-phenyl)acetic acid
C10H11IO4 (321.97020760000004)
5-[[(7-CHLORO-4-QUINOLINYL)SULFANYL]METHYL]-4-METHYL-4H-1,2,4-TRIAZOLE-3-THIOL
2-[(2-bromo-1,3-thiazol-5-yl)methyl]isoindole-1,3-dione
3-[(4-Bromophenyl)methoxy]-6-methyl-2-nitropyridine
C13H11BrN2O3 (321.99529959999995)
5-[2-(4-chlorophenyl)-1,3-thiazol-4-yl]-4-ethyl-4H-1,2,4-triazole-3-thiol
N,N-diethylcarbamodithioic acid (2,2,2-trichloro-1-formamidoethyl) ester
1,3-Bis(bromomethyl)-2,5-dimethoxybenzene
C10H12Br2O2 (321.92039719999997)
Trofosfamide
C9H18Cl3N2O2P (322.01714280000004)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01A - Alkylating agents > L01AA - Nitrogen mustard analogues D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D010752 - Phosphoramide Mustards C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D009676 - Noxae > D000477 - Alkylating Agents D009676 - Noxae > D009153 - Mutagens
p-Mercuribenzoate
D010575 - Pesticides > D005659 - Fungicides, Industrial > D010663 - Phenylmercury Compounds D004791 - Enzyme Inhibitors > D008626 - Mercuribenzoates
4-chloro-N-(4-chloro-2,5-dimethoxyphenyl)-5-dithiazolimine
C10H8Cl2N2O2S2 (321.94042479999996)
4-[(5-Bromo-8-quinolinyl)amino]-4-oxobutanoic acid
C13H11BrN2O3 (321.99529959999995)
2,5,6-Trichloro-1-(beta-D-erythrofuranosyl)benzimidazole
C11H9Cl3N2O3 (321.96787340000003)
2,2-dichloro-N-[1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide
α-D-Glucose-1-phosphate (disodium hydrate)
C6H13Na2O10P (322.00417280000005)
α-D-Glucose-1-phosphate disodium hydrate is used as a starting material for synthesis of glucuronic acid. α-D-Glucose-1-phosphate disodium hydrate can be used as a cytostatic compound essential for cardiopathic therapy, as an antibiotic, as an immunosuppressive agent, and as a circulatory system therapy element[1].